48 results about "Million Cells" patented technology

A fully-parallelized, highly-efficient compositional implicit hydrocarbon reservoir simulator is provided. The simulator is capable of solving giant reservoir models, of the type frequently encountered in the Middle East and elsewhere in the world, with fast turnaround time. The simulator may be implemented in a variety of computer platforms ranging from shared-memory and distributed-memory supercomputers to commercial and self-made clusters of personal computers. The performance capabilities enable analysis of reservoir models in full detail, using both fine geological characterization and detailed individual definition of the hydrocarbon components present in the reservoir fluids.

Sequence alignment and sequence database similarity searching are among the most important and challenging task in bio informatics, and are used for several purposes, including protein function prediction. An efficient parallelisation of the Smith-Waterman sequence alignment algorithm using parallel processing in the form of SIMD (Single-Instruction, Multiple-Data) technology is presented. The method has been implementation using the MMX (MultiMedia eXtensions) and SSE (Streaming SIMD Extensions) technology that is embedded in Intel's latest microprocessors, but the method can also be implemented using similar technology existing in other modern microprocessors. Near eight-fold speed-up relative to the fastest previously an optimised eight-way parallel processing approach achieved know non-parallel Smith-Waterman implementation on the same hardware. A speed of about 200 million cell updates per second has been obtained on a single Intel Pentium III 500 MHz microprocessor.

A method including in vitro stimulating a core cell population (CCP) of at least 5 million cells that have a density of less than 1.072 g/ml, and at least 1.5% of which are CD34+CD45−/dim, to differentiate into a neural progenitor/precursor cell population (NPCP). Other embodiments are also described.

The present invention provides processes for aseptically processing live mammalian cells in an aqueous medium to produce a cell suspension having a cell density of at least about 10 million cells/mL and cell viability of at least about 90%. These methods comprise a step of reducing the volume of the medium using a tangential flow filter (TFF) having a pore size of greater than 0.1 micron, during which step the trans-membrane pressure (TMP) is maintained at less than about 3 psi and the shear rate is maintained at less than about 4000 sec⁻¹. The invention also provides a complete process for large scale manufacturing mammalian cells for use in a therapeutic composition, and scalable, fully disposable systems for carrying out the process, using readily available disposables and pumps.

The invention discloses a few-cell-based whole genome chromatin high resolution conformation technology eHi-C2.0. A preparation method of a cell eHi-C2.0 sequencing library provided by the invention comprises the following steps of cracking cells to obtain chromatin; then, performing digestion on the chromatin; sequentially performing mark labeling and blunt end connection on the DNA subjected to the digestion to obtain cyclization products; introducing internal reference annular coprecipitation DNA molecules into the cyclization products; then, performing digestion by restrictive excision enzymes; then, performing ultrasonic interruption; next, grasping DNA fragments with the marks from the interruption products by using immunomagnetic beads; preparing the eHi-C2.0 sequencing library by the DNA fragments with the marks. The whole genome chromatin conformation technology eHi-C2.0 library building sequencing can be performed on the cell quantity as low as 0.1 million cells.

A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least 5 million cells that have a density of less than 1.072 g/ml, and at least 1% of which are CD34+CD45−/dim, to differentiate into a progenitor/precursor cell population (PCP). A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least ten thousand cells that have a density of less than 1.072 g/ml to differentiate into a progenitor/precursor cell population (PCP). A method is provided, including separating lower density cells from higher density cells, the lower density cells defining an initiating cell population (ICP), and in vitro stimulating the ICP to differentiate into a progenitor/precursor cell population (PCP). Other embodiments are also described.

The invention involves a kind to be good lowly, using the sea water cultivation effect bears the salty rapana thomasiana microbial inoculum using the microbial inoculum raise expense the application raise technology. Bears the salty red spirillum the selective breeding for to concentrate, the plate separation, the strain function selective breeding from the sea water, bears the salty red spirillum function strain. Using raise technology including culture medium optimization and application raise craft condition improvement. The culture medium optimization is from carbon source, nitrogen source, ingredient and so on inorganic salt and growth factor carries on the optimization, obtains reduces 47% culture medium ingredient the application formula. Uses the application formula postpositioned using the microbial inoculum raise, the vaccination under the white plastic warm awning the sunlight raise. The invention bears the salty rapana thomasiana strain to be possible to grow under the 0.1~~4%NaCl density, in the fresh water, the sea water cultivation may receive the good application effect. It greatly reduced the photosynthesis bacilliculture cost and the equipment using the raise technology invests. Bears the salty rapana thomasiana microbial inoculum the application raise to issue each milliliter hundred million cells in the above condition the use density to request.

Described herein is a rapid continuous biomanufacturing platform process that combines a perfusion mammalian cell culture with a synchronized purification of the antibodies produced by the cell culture without the use of intermediate media holding tanks or other large retention devices. This method described herein includes continuous cell culture of mammalian cells expressing the biological of interest and comprising a cell retention device wherein the perfusion of fresh media into the reactor and hence the harvest rate of antibody containing spent media from the reactor has a rate of 1 vessel volume per day (vvd) or less obtained by glucose control with a cell density of between 40 million cell/ml and 60 million cell/nil. Immediate recovery and purification of the antibody is obtained by synchronizing the rate of perfusion with the antibody capture and elution step cycle in a column that contains affinity resin that is between 0.01 and 0.001 times the volume of the bioreactor. The perfusion rate and capture rate were perfectly synchronized by extensive method and media development resulting in equal rates and eliminating the need for holding tanks and cell bleeding. The result is an order of magnitude faster antibody production as compared to conventional fed-batch mode.

The invention provides a method of breeding artemia in high density under alga cultivation environment. In an artemia cultivation water environment, the density of algae is one million cells/mL to ten million cells/mL; the water environment contains pseudomonas aeruginosa whose concentration is 10<6> to 10<8>/mL; the density of artemia is 5 to 12/mL; and the optimized density of artemia is 5 to 10/mL. The method increases dissolved oxygen in water and not only solves the problem of initial feed of artemia, but also solves the problem of low survival rate and spawning rate of high density cultivation. The method is also suitable in large aquaculture pond for guaranteeing stable water environment and survival rate.

A digital pathology system and associated method and computer program product provide a quantitative analysis of entire tissue slides as well as intuitive, effective, fast, and precise quantification of biomarker expressions across relevant areas of the entire tissue slides. The digital pathology system enables a novel workflow that allows the user to efficiently outline clinically relevant morphology in its entirety, including solid tumor areas. Quantitative analysis results are then efficiently and intuitively provided to the user for all tissue content (i.e., millions of cells) within seconds. This efficiency is made possible by a pre-computation step that computes and stores image analysis results for later retrieval. Visualizing vast amount of data effectively is another component of the system that provides information and confidence to the user about the biomarker expression levels.

The invention belongs to the field of biotechnology, particularly relates to the field of virus detection, and more particularly relates to a PCR primer group, probe and kit and detection method for detecting human immunodeficiency virus-1 2-LTR DNA. The detection primer group provided by the invention comprises nucleotide sequences shown as SEQ ID NO: 1-6; and the detection probe comprises nucleotide sequences shown as SEQ ID NO: 7-8. The detection primer group provided by the invention is different from the conventional real-time fluorescence quantitative PCR; through introduction of 3 pairs of real-time fluorescent quantitative PCR primers, that is, 6 primers, adoption of multiple cycles, and increase of the primer annealing temperature, the PCR detection method for detecting the HIV-1 2-LTR DNA, provided by the invention, achieves extremely high sensitivity and specificity, and the minimum detection limit can reach 2 copies per million cells in each PCR; and moreover, when a quantitative cell reaction system is further added in the PCR reaction, the HIV-1 2-LTR DNA and the number of cells can be quantified at the same time in the same PCR reaction (in the conventional method, the cell count is additionally required).

A preparation method of a specific peptide fragment mass spectrometry sample comprises the following steps: A, taking sample cells to be analyzed, collecting more than 2 million cells in a biotin culture environment, dissolving the cells in a cell lysis buffer solution, carrying out ultrasonic lysis, quantifying the concentration of a protein solution, and carrying out trypsin digestion of a peptide fragment; B, digesting the peptide fragment by a trypsin method; carrying out freeze-drying at-80 DEG C after digestion; C, preparing a biotin antibody combined with Protein G beads; D: using 1 mlof capture buffer solution to dissolve the obtained freeze-dried peptide fragments; E, combining antibodies and peptide fragments in the step C and the step D, incubating at 4 DEG C for 2 hours, and eluting with an elution buffer solution for 4 times; and F, loading 200 microliters of microfiltration column prepared by a gun head into the total supernate through a 3M C18 solid-phase extraction membrane, eluting to remove salt, dissolving peptide fragments, and carrying out mass spectrometric detection. According to the method, the natural biotinylated protein in the cell can be accurately checked.

The invention provides a kit for detecting lymphoid blood cancers such as T/B leukemia, lymphoma and myeloma minimal residual diseases based on research and development of high-throughput sequencing.The kit comprises multiplex-PCR primer sets for detecting IGH(VDJ), IGH(DJ), IGK, IGL, TCRbeta, TCRgamma, TCRdelta, BCL1/IGH and BCL2/IGH and with UMB (Unique Molecular Barcode, single-molecular labels), House Keeping gene PCR primer pairs, Multiplex PCR Mix(2X), internal reference DNA, Nuclease-Free Water, Elution Buffer, and primers and label sequences required for high-throughput sequencing. Bythe adoption of the kit, newly-mutant cancer cells can be found while the cancer cells are detected, the high-throughput sequencing technology is applied and combined with bioinformatic analysis, forthe detection sensitivity of MRD, one cancer cell can be at least detected in 1 million cells, that is to say, the probability is 10<-6>(0.0001%), the purpose of detecting the minimal residual diseases through quantitative analysis of the number of the cancer cells can be achieved, and sequence reading errors generated in the sequence mutation and library sequencing process due to base group mismatch during PCR amplification can be corrected.

A blood product containing peripheral blood mononuclear cells (PBMCs) in an amount of at least 4 million cells per milliliter and human chorionic gonadotropin (HCG in an amount of at least 150 international units (IU) per milliliter. A method of preparing the blood product, including applying HCG to a female patient, then obtaining PBMCs from the female patient, then adding HCG to the obtained PBMCs. A method of culturing PBMCs, including applying HCG to a female patient, then culturing PBMCs obtained from the female patient at a time after the HCG was applied to the patient. A method of in vitro fertilization, including applying HCG to a female patient, culturing PBMCs obtained from the patient after the HCG was applied to the patient, introducing the cultured PBMCs into the uterus of the patient, and transferring at least one embryo into the uterus of the patient.

An automated method for the production of cells and/or biomolecules such as protein or peptides includes culturing cells in at least one high cell density bioreactor, thereby fluidly connecting said bioreactor with a culture medium supply and a gas or gaseous mixture; fluidly connecting said bioreactor with a downstream unit; and growing cells to a density at least 50 million cells per ml. The total volume of the bioreactor is at least 10 liters. A system suitable for implementation of the automated method above is a small-scale and cupboard-sized system, which can be placed in a portable clean room.

A composition of matter is provided, comprising a population of cultured cells that comprises a sub-population of cells that both stain as CD31Bright and demonstrate uptake of Ac-LDL+, and secrete IL-8. A method is also provided, comprising stimulating in vitro an initiating cell population (ICP) of at least 5 million cells that have a density of less than 1.072 g/ml, wherein at least 1% of the cells of the ICP is CD34+CD45−/Dim, and at least 25% of the cells of the ICP are CD31Bright, to differentiate into a progenitor/precursor cell population (PCP). Other embodiments are also described.

The invention discloses a method for separating Pig-a gene mutant cells from cells cultured in vitro and application of the Pig-a gene mutant cells. The method comprises the following steps: (1) mixing an anti-GPI anchorage protein antibody marked by an immunofluorescent dye, magnetic beads resisting the immunofluorescent dye and the cells; and (2) separating cells marked by the magnetic beads from cells not marked by the magnetic beads, wherein the cells marked by the magnetic beads being Pig-a gene mutation negative cells, and the cells not marked by the magnetic beads being Pig-a gene mutation positive cells. The method provided by the invention has higher separation efficiency for removing cells, such as the Pig-a positive cells pre-stored in human lymphoblastic TK6 cells, can separate10 million cells within 15 minutes, and is simple to operate and low in cost.

A method for the treatment of acute stroke in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.

In accordance with an embodiment of the invention, there is provided a method for: a) high-throughput, multiplexed, affinity-based separation of proteins—especially low abundance proteins—from complex biological mixtures such as serum; and b) high-throughput, multiplexed, affinity-based separation of cells—especially rare cells—from complex biological mixtures such as blood or blood fractions. The separation of proteins or cells is achieved based on differential binding to affinity-capture beads of different sizes and then sorting the protein-bound or cell-bound beads using the concept of centrifugal-induced Dean migration in a spiral microfluidic device. This method enables continuous-flow, high throughput affinity-separation of milligram-scale protein samples or millions of cells in minutes after binding. This is particularly applicable to the isolation of antigen-specific antibodies from polyclonal sera and antigen-specific immune cells or circulating tumor cells from blood, both of which are otherwise highly labor-intensive and expensive to perform.

The use of endometrial regenerative cells (ERC) and other endometrial originating cells for the treatment of traumatic brain injury is disclosed. In one embodiment a patient is administered a population of CD90 positive, CD105 positive, allogeneic regenerative cells subsequent to a brain injury. Cell concentration, frequency of administration, and route of administration may be determined based on extent of injury, inflammatory response and endogenous stem cell mobilization. In one embodiment, a patient suffering from traumatic brain injury is administered a dose of 100 million Endometrial Regenerative Cells intravenously at a rate of 1 million cells per minute in a volume of 100 ml of saline.

A method for the treatment of macular oedema and degeneration in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.